.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Treatment of Metastatic Colorectal Cancer

EP. 1: TRIBE Trial: First-Line Treatment of mCRC

September 29th 2013

EP. 2: PRIME Trial: RAS Mutations in Metastatic Colorectal Cancer

September 29th 2013

EP. 3: EPOC Studies: Preoperative Treatments in CRC

September 29th 2013

EP. 4: FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC

September 29th 2013

EP. 5: Predictive Value of RAS Mutations in mCRC

September 29th 2013

EP. 6: Case Study: Borderline Resectable mCRC

September 29th 2013

EP. 7: Maintenance Therapy in Metastatic Colorectal Cancer

September 29th 2013

EP. 8: Antiangiogenic Therapy in Metastatic Colorectal Cancer

September 29th 2013

EP. 9: Second-Line and Salvage Treatment of mCRC

September 29th 2013

EP. 10: Novel Therapies in Development for mCRC

September 29th 2013

EP. 11: Personalized Medicine in Colorectal Cancer

September 29th 2013